JAMA

GLP-1 Agonists, Like Ozempic and Wegovy, Have Risk of Gut Issues: Study
BioSpace
Thu, 10/5/23 - 09:07 pm
Novo Nordisk
Ozempic
Wegovy
GLP-1 agonist
JAMA
JAMA: Leqembi could cost Medicare up to $5B per year
Medical Marketing and Media
Mon, 05/15/23 - 06:20 pm
Biogen
Eisai
Leqembi
drug pricing
Medicare
Alzheimer's disease
JAMA
Study: Half of confirmatory studies for accelerated approvals are late
RAPS.org
Tue, 04/4/23 - 11:20 pm
JAMA
regulatory
accelerated approvals
Study finds manufacturers spend more to advertise less beneficial drugs
RAPS.org
Tue, 02/14/23 - 10:50 am
JAMA
DTC advertising
pharma advertising
Broken promises? FDA needs more power to remove drugs from marketplace, JAMA analysis finds
Endpoints
Sun, 12/11/22 - 01:22 pm
JAMA
FDA
clinical trials
Study: Public funding was instrumental to early development of COVID therapeutics, vaccines
RAPS.org
Wed, 08/17/22 - 11:25 pm
COVID-19
pandemic
JAMA
funding
vaccines
JAMA study finds cancer drug data is still largely unavailable to qualified researchers
Endpoints
Mon, 08/1/22 - 10:30 am
JAMA
oncology
cancer
clinical trials
A New JAMA Study Misleads About Drug Prices—And Launches a New Attack on Patients with Ultra-Rare Diseases
Drug Channels
Tue, 06/14/22 - 11:11 am
JAMA
drug pricing
Study: FDA approves new oncology drugs quicker than EMA
RAPS.org
Mon, 06/13/22 - 10:33 am
JAMA
regulatory
drug approvals
FDA
EMA
Europe
JAMA Paper Withdrawal Adds One More Layer to Aduhelm Controversy
BioSpace
Wed, 07/28/21 - 11:15 pm
Biogen
Aduhelm
Alzheimer's disease
JAMA
FDA staffers defend Aduhelm approval in JAMA editorial
Pharmaforum
Wed, 07/14/21 - 10:18 am
FDA
Biogen
Aduhelm
JAMA
drug approvals
Alzheimer's disease
Americans Are Dying In The Pandemic At Rates Far Higher Than In Other Countries
NPR
Wed, 10/14/20 - 10:48 am
pandemic
COVID-19
JAMA
Policy makers should ‘set their sights higher’ on U.S. drug pricing regulations, researchers say
MedCity News
Tue, 09/29/20 - 12:02 pm
drug pricing
JAMA
legislation
Merck CEO Frazier finds fault in new studies suggesting pharma profits are too high
Fierce Pharma
Wed, 03/4/20 - 12:00 am
JAMA
profits
Merck
Ken Frazier
Pharma CEOs
Researchers Call on FDA to Rethink Guidance Allowing Use of Surrogate Outcomes
RAPS.org
Thu, 11/14/19 - 07:36 pm
FDA
JAMA
infectious diseases
drug development
surrogate endpoints
JAMA: Withdraw This Flawed and Inaccurate Article About the 340B Program and Drug Prices
Drug Channels
Tue, 07/16/19 - 11:10 pm
JAMA
drug pricing
340B
hepatitis C
Financial disclosure lacking in publication of clinical trials, study finds
Science Daily
Fri, 08/31/18 - 10:35 am
oncologists
physicians
physician payments
JAMA
scientific journals
cancer
Copay exceeds drug cost in 23% of claims: JAMA research
Biopharma Dive
Wed, 03/14/18 - 09:32 pm
copays
JAMA
drug pricing
Doctors with restricted sales-rep access prescribed fewer promoted meds: JAMA
Fierce Pharma
Thu, 05/4/17 - 10:12 am
physicians
drug reps
physician access
JAMA
Amgen refutes 'flawed' cholesterol study
BioPharma Dive
Mon, 08/22/16 - 10:06 pm
Amgen
PCSK9 inhibitors
JAMA
Repatha

Pages